Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vitrafy Life Sciences Ltd. ( (AU:VFY) ) has shared an update.
Vitrafy Life Sciences has signed a 12‑month exclusive collaboration and development agreement with IMV Technologies, a French multinational and global leader in animal reproductive technologies, to integrate Vitrafy’s cryopreservation hardware and software into IMV’s established offering for farm animals and aquaculture. The deal provides Vitrafy with immediate monthly revenue of up to A$480,000 plus potential milestone payments, while giving IMV exclusive access to Vitrafy’s technology in farm animal and aquaculture assisted reproduction for the term, positioning both companies to co-develop a market-ready, globally scalable cryopreservation solution that could set a new benchmark in the sector and pave the way for a longer-term commercial agreement, broader market penetration and accelerated validation of Vitrafy’s platform.
The most recent analyst rating on (AU:VFY) stock is a Buy with a A$2.10 price target. To see the full list of analyst forecasts on Vitrafy Life Sciences Ltd. stock, see the AU:VFY Stock Forecast page.
More about Vitrafy Life Sciences Ltd.
Vitrafy Life Sciences Limited is an ASX-listed life sciences company specialising in next-generation, nitrogen-free cryopreservation technology, with applications in animal reproduction and human health. The company is pursuing a dual-market strategy, using the less-regulated global animal reproduction market to accelerate commercial scale while concurrently advancing its human health expansion, particularly in North America.
Average Trading Volume: 25,202
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$83.64M
For a thorough assessment of VFY stock, go to TipRanks’ Stock Analysis page.